B
Bernd Frericks
Researcher at Charité
Publications - 56
Citations - 1714
Bernd Frericks is an academic researcher from Charité. The author has contributed to research in topics: Ablation & Radiofrequency ablation. The author has an hindex of 24, co-authored 53 publications receiving 1637 citations. Previous affiliations of Bernd Frericks include Hochschule Hannover.
Papers
More filters
Journal ArticleDOI
Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.
Bernd Frericks,Christoph Loddenkemper,Alexander Huppertz,Steffi Valdeig,Andrea Stroux,Marion Seja,Karl-Jürgen Wolf,Thomas Albrecht +7 more
TL;DR: After Gd-EOB-DTPA injection, most HCCs showed typical arterial enhancement with early washout and Liver-to-lesion contrast was best at 20 minutes, and there was no correlation between the degree of enhancement at any time point and tumor grade.
Journal ArticleDOI
Multipolar radiofrequency ablation of hepatic tumors: initial experience.
TL;DR: The multipolar RF ablation device achieves large ablation zones and has high technical effectiveness in treating hepatic tumors in patients with hepatic malignancy.
Journal ArticleDOI
Outcome of patients with acute sigmoid diverticulitis: multivariate analysis of risk factors for free perforation.
TL;DR: The risk of free perforation in acute SD decreases with the number of previous episodes of SD, and the first episode thus is the most dangerous for a freePerforation.
Journal ArticleDOI
3D CT modeling of hepatic vessel architecture and volume calculation in living donated liver transplantation.
Bernd Frericks,Franco C. Caldarone,Björn Nashan,Dagmar Högemann Savellano,Georg Stamm,Timm Kirchhoff,Hoen-oh Shin,Andrea Schenk,Dirk Selle,Wolf Spindler,Jürgen Klempnauer,Heinz-Otto Peitgen,Michael Galanski +12 more
TL;DR: A novel image processing technique was evaluated which allows a semi-automatic volume calculation and 3D visualisation of the different liver segments and no significant differences between the presented automatic volumetry and the conventional volumets were observed.
Journal ArticleDOI
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial
Christian Scholz,Antonello Pinto,Werner Linkesch,Ola Lindén,Andreas Viardot,Ulrich Keller,Georg Hess,Secondo Lastoria,Kristina Lerch,Ferdinando Frigeri,Manuela Arcamone,Andrea Stroux,Bernd Frericks,Christiane Pott,Antonio Pezzutto +14 more
TL;DR: YIT is well tolerated and achieves high response rates, and individuals in remission 1 year after (90)YIT appear to have long- lasting responses.